Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus
Vascular Pharmacology · 2024
DOI: 10.1016/j.vph.2024.107432 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2024. Verfasst von Giovanna Manzi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161…. Hauptthemen laut MEDLINE: Antihypertensive Agents, Consensus, Phosphodiesterase 5 Inhibitors, Pulmonary Arterial Hypertension. Die Arbeit nennt 73 Literaturangaben.
Abstract (Originalsprache)
Despite the innovations introduced in the 2022 European Society of Cardiology/European Respiratory Society Guidelines on Pulmonary Hypertension, risk discrimination and management of pulmonary arterial hypertension (PAH) patients at intermediate risk still represents a grey zone. Additionally, clinical evidence derived from currently available studies is limited. This expert panel survey intends to aid physicians in choosing the best therapeutic strategy for patients at intermediate risk despite ongoing oral therapy. An expert panel of 24 physicians, specialized in cardiology and/or pulmonology with expertise in handling all drugs available for the treatment of PAH participated in the survey. All potential therapeutic options for patients at intermediate risk were explored and analyzed to produce graded consensus statements regarding: the switch from endothelin receptor antagonist (ERA) or phosphodiesterase 5 inhibitor (PDE5i) to another oral drug of the same class; the addition of a drug targeting the prostacyclin pathway administered by different routes; the switch from PDE5i to riociguat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161 Rome, Italy.
- Department of Cardiology, Mount Sinai Icahn School of Medicine, New York, NY, United States of America.
- Department of Cardiology, Monaldi Hospital - University "L. Vanvitelli", Naples, Italy.
- Clinical and Interventional Cardiology, Sassari University Hospital, Sassari, Italy.
- Cardiology Unit, Cardiovascular Department, ARNAS "G.Brotzu", Cagliari, Italy.
- Cardiothoracic Department, Policlinico Riuniti University Hospital, 71100 Foggia, Italy.
Zitieren
APA
Manzi, G., Benza, R. L., Argiento, P., Casu, G., Corda, M., Correale, M., D'Alto, M., Galgano, G., Garascia, A., Ghio, S., Gomberg-Maitland, M., Mulé, M., Paciocco, G., Papa, S., Prati, D., Preston, I. R., Raineri, C., Romeo, E., Scelsi, L., …, & Vizza, C. D. (2024). Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2024.107432
Vancouver
Manzi G, Benza RL, Argiento P, Casu G, Corda M, Correale M, et al. Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus. Vascular Pharmacology. 2024. doi:10.1016/j.vph.2024.107432
BibTeX
@article{Manzi2024,
author = {Manzi, Giovanna and Benza, Raymond L and Argiento, Paola and Casu, Gavino and Corda, Marco and Correale, Michele and D'Alto, Michele and Galgano, Giuseppe and Garascia, Andrea and Ghio, Stefano and Gomberg-Maitland, Mardi and Mulé, Massimiliano and Paciocco, Giuseppe and Papa, Silvia and Prati, Daniele and Preston, Ioana R and Raineri, Claudia and Romeo, Emanuele and Scelsi, Laura and Stolfo, Davide and Vitulo, Patrizio and White, R James and Badagliacca, Roberto and Vizza, Carmine Dario},
title = {Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus},
journal = {Vascular Pharmacology},
year = {2024},
doi = {10.1016/j.vph.2024.107432}
}
EUVIMED